Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Short Interest Up ? in May

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) was the target of a significant increase in short interest during the month of May. As of May 15th, there was short interest totaling 86,503 shares, an increase of ? from the April 30th total of 0 shares. Based on an average daily trading volume, of 426,652 shares, the short-interest ratio is currently 0.2 days. Currently, 0.2% of the shares of the company are short sold.

Insider Buying and Selling at Odyssey Therapeutics

In other Odyssey Therapeutics news, major shareholder Sr One Capital Management, Llc sold 1,780 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $18.00, for a total value of $32,040.00. Following the completion of the sale, the insider owned 440,981 shares in the company, valued at $7,937,658. This represents a 0.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Tpg Gp A, Llc purchased 1,388,889 shares of Odyssey Therapeutics stock in a transaction on Monday, May 11th. The stock was bought at an average price of $18.00 per share, with a total value of $25,000,002.00. Following the transaction, the insider owned 3,690,146 shares of the company’s stock, valued at approximately $66,422,628. This represents a 60.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought 4,183,777 shares of company stock valued at $75,319,986 in the last quarter.

Odyssey Therapeutics Price Performance

Odyssey Therapeutics stock traded down $0.64 during trading hours on Wednesday, hitting $16.29. The company had a trading volume of 107,935 shares, compared to its average volume of 324,055. Odyssey Therapeutics has a 1 year low of $15.35 and a 1 year high of $20.30.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Wedbush began coverage on shares of Odyssey Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $30.00 target price for the company. Oppenheimer started coverage on Odyssey Therapeutics in a report on Tuesday. They set an “outperform” rating and a $40.00 price target for the company. Wall Street Zen upgraded Odyssey Therapeutics to a “hold” rating in a report on Saturday, May 16th. JPMorgan Chase & Co. started coverage on Odyssey Therapeutics in a report on Tuesday. They set an “overweight” rating and a $26.00 price target for the company. Finally, Cantor Fitzgerald began coverage on shares of Odyssey Therapeutics in a research note on Tuesday. They issued an “overweight” rating for the company. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $32.00.